Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MET233 and MET097 in Obesity or Overweight
NCT06924320Phase 2Completed
- Sponsor
- Pfizer
- Start
- Mar 2025
- Primary completion
- Sep 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MET-233, PF-08653944 in obesity, sponsored by Pfizer. Started Mar 2025; status: completed.
02
Drugs
MET-233PF-08653944
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06924320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06924320.